Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399975 | PMC |
| http://dx.doi.org/10.1007/s10354-022-00962-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Qualitative methods: the missing link in orthopaedic research.
Bone Joint Res
January 2025
The Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology Medicine and Health, The University of Manchester, London, United Kingdom.
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study.
Dermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Millets for food security and agricultural sustainability.
Planta
January 2025
School of Molecular and Cellular Biology, Centre for Plant Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Routine symptom screening and supportive care needs.
Support Care Cancer
January 2025
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universita' Degli Studi Di Brescia, Brescia, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!